1. Home
  2. POLE vs RZLT Comparison

POLE vs RZLT Comparison

Compare POLE & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POLE
  • RZLT
  • Stock Information
  • Founded
  • POLE 2024
  • RZLT 2010
  • Country
  • POLE United States
  • RZLT United States
  • Employees
  • POLE N/A
  • RZLT N/A
  • Industry
  • POLE
  • RZLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • POLE
  • RZLT Health Care
  • Exchange
  • POLE NYSE
  • RZLT Nasdaq
  • Market Cap
  • POLE 296.0M
  • RZLT 226.4M
  • IPO Year
  • POLE 2024
  • RZLT N/A
  • Fundamental
  • Price
  • POLE $10.13
  • RZLT $3.33
  • Analyst Decision
  • POLE
  • RZLT Strong Buy
  • Analyst Count
  • POLE 0
  • RZLT 8
  • Target Price
  • POLE N/A
  • RZLT $12.00
  • AVG Volume (30 Days)
  • POLE 3.8K
  • RZLT 482.0K
  • Earning Date
  • POLE 01-01-0001
  • RZLT 05-14-2025
  • Dividend Yield
  • POLE N/A
  • RZLT N/A
  • EPS Growth
  • POLE N/A
  • RZLT N/A
  • EPS
  • POLE N/A
  • RZLT N/A
  • Revenue
  • POLE N/A
  • RZLT N/A
  • Revenue This Year
  • POLE N/A
  • RZLT N/A
  • Revenue Next Year
  • POLE N/A
  • RZLT N/A
  • P/E Ratio
  • POLE N/A
  • RZLT N/A
  • Revenue Growth
  • POLE N/A
  • RZLT N/A
  • 52 Week Low
  • POLE $9.94
  • RZLT $1.76
  • 52 Week High
  • POLE $11.16
  • RZLT $6.19
  • Technical
  • Relative Strength Index (RSI)
  • POLE N/A
  • RZLT 28.66
  • Support Level
  • POLE N/A
  • RZLT $3.25
  • Resistance Level
  • POLE N/A
  • RZLT $3.81
  • Average True Range (ATR)
  • POLE 0.00
  • RZLT 0.24
  • MACD
  • POLE 0.00
  • RZLT -0.04
  • Stochastic Oscillator
  • POLE 0.00
  • RZLT 6.72

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Share on Social Networks: